Skip to main content
. 2024 Mar;30(3):478–489. doi: 10.3201/eid3003.230893

Figure 3.

Figure 3

Vaccine effectiveness against hospitalization among persons >65 years of age in a population-based evaluation of vaccine effectiveness against SARS-CoV-2 infection, severe illness, and death, Taiwan, March 22, 2021–September 30, 2022. The study investigated various vaccine types: mRNA (Pfizer-BioNTech BNT162b2 [https://www.pfizer.com] and Moderna mRNA-1273 [https://www.modernatx.com]), protein subunit (Medigen MVC-COV1901 [https://www.medigenvac.com]), and viral vector-based vaccines (Oxford-AstraZeneca AZD1222 [https://www.astrazeneca.com]). The forest plot demonstrates effectiveness of different vaccination regimens status against moderate and severe illness defined by hospitalization for persons >65 years of age. Red dots indicate percentage effectiveness; bars indicate 95% CIs. AZ, AstraZeneca vaccine.